Background: Solitary fibrous tumor/hemangiopericytomas (SFT/HPCs) are rare mesenchymal tumors of nonmeningothelial origin that comprises <1% of all central nervous system tumors.
Case Description: A 45-year-old male presented with sleep apnea (apnea-hypopnea index was 17.1 events/hour) and dysesthesias of the right upper and lower extremities. The magnetic resonance demonstrated a heterogeneous intradural extra-axial C1 mass with syringobulbia and syringomyelia. The right vertebral angiography revealed a hypervascular mass (i.e., intense tumor staining). With the preoperative diagnosis of a spinal hemangioblastoma, the patient underwent tumor removal. However, intraoperative findings demonstrated that the ventral component of the tumor was intramedullary without a dural attachment. Further, the histological diagnosis was consistent with SFT/HPC (HPC phenotype). The postoperative course was uneventful, and the patient's symptoms and the syrinxes spontaneously regressed.
Conclusion: A 45-year-old male presented a rare spinal intradural lesion at C1 appeared to be a spinal hemangioblastoma, but proved to be SFT/HPC (HPC phenotype) with intramedullary invasion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610592 | PMC |
| http://dx.doi.org/10.25259/SNI_655_2022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[CD34-negative solitary fibrous tumor in prostate: report of a case].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing210011, China.
[Intracranial mesenchymal tumors with FET::CREB fusion: a clinicopathological analysis of six cases].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China.
To investigate the clinicopathological and molecular genetic characteristics of intracranial mesenchymal tumors with FET::CREB fusion transcript. The clinical and imaging data of 6 cases of intracranial mesenchymal tumors with FET::CREB fusion from December 2018 to December 2023 were collected at the First Affiliated Hospital of Zhengzhou University. Their histological features, immunophenotype and molecular characteristics were analyzed.
View Article and Find Full Text PDFCinematic rendering of pleural solitary fibrous tumor.
Radiol Case Rep
March 2025
Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 601 N Caroline St, Baltimore, MD, 21287, USA.
Solitary fibrous tumors are rare and typically benign fibroblastic neoplasms with a mean age of onset ranging from 60 to 70 years. Solitary fibrous tumors may arise anywhere within the body, however the pleura is the most common site of origin for these tumors, with approximately 30% of tumors arising from the pleura. In this report we highlight the case of a 62-year-old woman who presented with gradually progressive left sided chest pain that was eventually diagnosed as a pleural SFT.
View Article and Find Full Text PDFSurgical resection of a solitary fibrous tumour causing refractory hypoglycaemia: Doege-Potter syndrome.
BMJ Case Rep
January 2025
Department of Surgery, Sinai Grace Hospital, Detroit Medical Center, Detroit, Michigan, USA.
Solitary fibrous tumours (SFTs) are rare soft tissue masses that are often clinically silent until they cause mass effect. A paraneoplastic syndrome manifesting as persistent hypoglycaemia, termed Doege-Potter syndrome (DPS), can be associated with these lesions. Surgical treatment is recommended for the management of these tumours.
View Article and Find Full Text PDFIntroduction: Solitary fibrous bladder tumors are extremely uncommon, with only a few cases reported. These fibroblastic mesenchymal neoplasms are typically benign, indolent, and slow growing.
Case Presentation: A 44-year-old male patient with obstructive uropathy was referred to our unit for workup.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!